Advanced and recurrent endometrial cancer: State of the art and future perspectives

Francesca Tronconi; Camilla Nero; Elena Giudice; Vanda Salutari; Lucia Musacchio; Caterina Ricci; Maria Vittoria Carbone; Viola Ghizzoni; Maria Teresa Perri; Floriana Camarda; Marica Gentile; Rossana Berardi; Giovanni Scambia; Domenica Lorusso

doi:10.1016/j.critrevonc.2022.103851

Advanced and recurrent endometrial cancer: State of the art and future perspectives

Crit Rev Oncol Hematol. 2022 Dec:180:103851. doi: 10.1016/j.critrevonc.2022.103851. Epub 2022 Oct 17.

Affiliations

¹ Oncologic Clinic, Università Politecnica delle Marche, Via Conca 71, 60126 Torrette, Ancona, Italy; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
² Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
³ Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Roma, Largo Agostino Gemelli 8, 00168, Rome, Italy.
⁴ Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Medical Oncology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy.
⁵ Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Medical Oncology, Azienda Ospedaliero Universitaria Consorziale Policlinico, Piazza Giulio Cesare 11, 70124 Bari, BA, Italy.
⁶ Oncologic Clinic, Università Politecnica delle Marche, Via Conca 71, 60126 Torrette, Ancona, Italy.
⁷ Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Roma, Largo Agostino Gemelli 8, 00168, Rome, Italy.
⁸ Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Roma, Largo Agostino Gemelli 8, 00168, Rome, Italy. Electronic address: domenica.lorusso@policlinicogemelli.it.

PMID: 36257537
DOI: 10.1016/j.critrevonc.2022.103851

Abstract

Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available therapeutic options are limited. Current treatment is mainly based on platinum-based chemotherapy. Recently, the Food and Drug Administration (FDA) granted approval for the combination of pembrolizumab and lenvatinib for endometrial cancer patients without microsatellite instability (MSS) progressing on a previous line of therapy while European Medicines Agency (EMA) approved the combination for all comers patients failing previous platinum treatment. Anti programmed cell death protein-1 (PD-1) dostarlimab (TSR-042) was approved as monotherapy in patients with advanced, microsatellite instable (MSI) endometrial cancer progressing to platinum treatment. Phase II-III clinical trials in metastatic endometrial cancer are mainly focused on target therapies and immunotherapy as single agents or in combination. Unfortunately, most of these trials are lacking of predictive biomarkers of response to select patients most or at least likely to benefit from those treatments.

Keywords: Chemotherapy; Hormonal therapy; Immunotherapy; Metastatic endometrial cancer; Radiation treatment; Target therapy.

Publication types

Review

MeSH terms

Endometrial Neoplasms* / diagnosis
Endometrial Neoplasms* / drug therapy
Endometrial Neoplasms* / genetics
Female
Humans
Immunotherapy
Microsatellite Instability
Neoplasm Recurrence, Local* / drug therapy
Neoplasm Recurrence, Local* / genetics

Substances

dostarlimab